固形腫瘍からの軟髄膜転移に対する免疫チェックポイント阻害剤とペメトレキセドくも膜下腔内注射の併用
固形腫瘍からの軟髄膜転移に対する免疫チェックポイント阻害剤とペメトレキセドくも膜下腔内注射の併用:第I/II相試験
This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors. The primary objective was to assess recommended dose and safety based on adverse events (AEs). All participants were observed to evaluate the clinical response rate (CRR), disease control rate (DCR) and overall survival (OS). Patients underwent cerebrospinal fluid (CSF) and blood specimen collection to evaluate potential clinical, molecular, and/or immune predictors of treatment efficacy and safety.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
-
Beijing、中国、101100
- Beijing Chest Hospital, Capital Medical University
-
Beijing、中国
- Cancer Center, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine
-
Shanghai、中国
- Jinshan Hospital, Fudan University
-
-
Guangdong
-
Huizhou、Guangdong、中国、516000
- The Affiliated Huizhou Hospital, Guangzhou Medical University
-
Huizhou、Guangdong、中国
- Huizhou First Hospital Affiliated to Guangdong Medical University
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of solid tumors; Cerebrospinal fluid cytopathology is positive.
- Male or female aged between 18 and 75 years; Normal liver and kidney function; WBC≥4000/mm3, Plt≥100000/mm3.
- No history of severe nervous system disease; No severe dyscrasia.
Exclusion Criteria:
- Any evidence of nervous system failure, including severe encephalopathy, grade 3 or 4 leukoencephalopathy on imaging, and Glasgow Coma Score less than 11.
- Any evidence of extensive and lethal progressive systemic diseases without effective treatment.
- A history of HIV or AIDS, active hepatitis B or C infection, previous anti-PD1 therapy-induced pneumonitis, or have ongoing >Grade 2 adverse events of such therapy; or ongoing autoimmune disease that required systemic treatment in the past 2 years.
- Patients with poor compliance or other reasons that were unsuitable for this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Group
Immune checkpoint inhibitor combined with pemetrexed |
Drug 1: Toripalimab 40 mg; Drug 2: pemetrexed 15mg. intrathecal injection therapy |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Recommended dose
時間枠:The dose limiting toxicity will be evaluated during the first 6 weeks of study treatment (the DLT window).
|
The recommended dose of intrathecal PD-1 inhibitor. The dose limiting toxicity was defined as ≥ grade 3 neurological toxicities (e.g., chemical meningitis) or other grade 4 toxicity. |
The dose limiting toxicity will be evaluated during the first 6 weeks of study treatment (the DLT window).
|
|
Incidence of treatment-related adverse events
時間枠:From date of treatment until discontinuation of study treatment.
|
The incidence of treatment-related adverse events were measured for determining tolerability and safety. Adverse events (AEs) are evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). Events of grade 3-5 are defined as moderate and severe adverse events. |
From date of treatment until discontinuation of study treatment.
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinical response rate
時間枠:From date of treatment until the date of first documented progression or date of death from any cause, whichever came first.
|
The response assessment in neuro-oncology criteria (RANO) proposal for response criteria of leptomeningeal metastasis was used to assess the clinical response in this study. |
From date of treatment until the date of first documented progression or date of death from any cause, whichever came first.
|
|
Progression-free survival related to leptomeningeal metastasis (LMPFS)
時間枠:From enrollment to LM progression or death, whichever occurred first, or the last follow-up (at least 7 months).
|
LMPFS was defined as time from the enrollment until leptomeningeal metastasis progression or death, whichever occurred first. The leptomeningeal metastasis progression was determined based on the RANO proposal evaluation criteria which have been established and published on Neuro Oncol. |
From enrollment to LM progression or death, whichever occurred first, or the last follow-up (at least 7 months).
|
|
Overall survival(OS)
時間枠:From the enrollment of this study until date of death from any cause, whichever came first, or the last follow-up (at least 7 months).
|
Survival time was recorded since the date of patient enrollment. All patients were followed up until death or the end of the study. |
From the enrollment of this study until date of death from any cause, whichever came first, or the last follow-up (at least 7 months).
|
|
Disease control rate
時間枠:From date of treatment until the date of first documented progression or date of death from any cause, whichever came first.
|
Disease control rate is defined as the proportion who achieve an leptomeningeal metastasis response or stable disease. |
From date of treatment until the date of first documented progression or date of death from any cause, whichever came first.
|
協力者と研究者
協力者
協力者
出版物と役立つリンク
一般刊行物
- Pan Z, Yang G, Cui J, Li W, Li Y, Gao P, Jiang T, Sun Y, Dong L, Song Y, Zhao G. A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer. Front Oncol. 2019 Aug 30;9:838. doi: 10.3389/fonc.2019.00838. eCollection 2019.
- Glitza Oliva IC, Ferguson SD, Bassett R Jr, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Carapeto FCL, Hudgens CW, Huse JT, Tetzlaff MT, Burton EM, Tawbi HA, Davies MA. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 Apr;29(4):898-905. doi: 10.1038/s41591-022-02170-x. Epub 2023 Mar 30.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- TPLM
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
All individual participant data that underlie results in a publication will be available to other researchers.
IPD 共有時間枠
Starting 6 months after publication
IPD 共有アクセス基準
Individual participant data will be public accessable via contacting with principal investigator by email within 6 months after the trial complete
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。